Company: DNLI
Filing Date: 2025-03-05
Form Type: 8-K
Source: 0001714899-25-000072
Chunk: 0

Company: Denali Therapeutics Inc.
Filing Date: 2025-03-05
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On March 5, 2025, Denali Therapeutics Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS) did not demonstrate a treatment effect on neurofilament light (NfL), a biomarker of neuronal damage, over the 24-week, double-blind period and in a subset of participants that completed an additional 28 weeks in the open-label active treatment extension.

On January 6, 2025, Denali announced that the study did not meet the primary endpoint of efficacy in slowing disease progression as compared with placebo. Key secondary endpoints were also not statistically different between the active and placebo groups at week 24.

Based on these outcomes, the active treatment extension in Regimen G will be discontinued. Overall, DNL343 was found to be safe and well tolerated. Data from Regimen G will be presented at a future medical meeting. Denali intends to assess potential future development opportunities for DNL343.

The information furnished in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Certain statements in this report are forward looking, such as those regarding the timing and presentation of Regimen G data and plans for the future development of DNL343. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Denali may be found in Denali’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “ SEC”) on February 27, 2025, and Denali’s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.

  Exhibit No.      Description                                                  
 ────────────────────────────────────────────────────────────────────────────────
          104      Cover